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occurred in 5 patients (1.8%). There were more female, adenocarci-
noma patients in N2 group (p<0.05); however, T stage was not different 
between N1 and N2 groups. The number of metastatic lymph nodes and 
nodal stations were 5.6 ± 5.6 and 2.5 ± 1.4 in N2 group, which were 
signiﬁcantly higher than 2.3 ± 1.7 and 1.2 ± 0.5 of N1 group (p<0.05). 
The overall 5-year survivals of N1 and N2 groups were 62.0% and 
39.6% (p<0.05). Multivariate analysis revealed that the age and the 
number of metastatic nodal stations were signiﬁcant risk factors for 
overall survival (p<0.05), however, N2 disease was not a signiﬁcant 
risk factor. The 5-year survival of patients with 1, 2, and 3 metastatic 
nodal stations were 68.4%, 32.3%, and 0% in N1 group, and 68.2%, 
32.0%, and 15.0% in N2 group, which did not show signiﬁcant differ-
ence between N1 and N2 groups.
Conclusions: In our study, multiplicity of metastatic nodal station 
signiﬁcantly affected overall survival in NSCLC with nodal metastasis 
rather than the locations of metastatic lymph node. Worse prognosis of 
N2 disease than N1 disease was due to the high probability of multiple 
metastatic nodal stations of N2 disease.
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Background: The 5-year survival rate after complete resection of non-
small cell lung cancer has improved with the decades from 41% in the 
1970’s, to 58% in the 1980’s, 63% in the 1990’s, to 78% since 2000. 
Factors related to the improvement were analyzed. 
Method: We used the survival index to ascertain how the 5-year sur-
vival rate of patients changed with the decade according to stage of the 
disease. The survival index was calculated by multiplying the propor-
tion of cases by the 5-year survival rate at each stage.
Results: The proportion of stage I cases was 54% in the 1970’s, and in-
creased to 64% in the 1980’s, 70% in the 1990’s, and 79% since 2000. 
The 5-year survival rate of stage I patients was 58% in the 1970’s, 
and increased to 71% in the 1980’s, 76% in the 1990’s, and 85% since 
2000. The survival index of stage I increased from 32 in the 1970’s, 
to 45 in the 1980’s, 53 in the 1990’s, and 67 since 2000. The stage I 
cases were then sub-classiﬁed in to stage IA and stage IB cases and the 
survival index of the stage IA cases increased from 18 in the 1970’s, 
to 29 in the 1980’s, 39 in the 1990’s, and 53 since 2000. The propor-
tion of stage IA cases detected by a lung cancer mass screening system 
increased from 17% in the 1970’s, to 28% in the 1980’s, 33% in the 
1990’s, and 37% since 2000.
Decade
survival 
rate(%)
Survival index (proportion of cases % × survival rate %)
p-I p-II p-III p-IV
1970-1979
(N=186)
41 32
(54×58)
7
(23×33)
2
(22×10)
0
(1×0)
1980-1989 58 45
(64×71)
8
(16×50%)
5
(20×25)
0
(1×0)(N=630)
1990-1999 63 53
(70×76)
5
(13×42)
5
(18×29)
0
(0×0)(N=1234)
2000-2005 78 67
(79×85)
7
(11×59)
4
(10×36)
0
(0×0)(N=1003)
Conclusion: As the lung cancer mass screening system has come into 
widespread use in Japan, the number of stage IA lung cancer cases 
that have been detected has increased, and because of that the surgical 
results have improved with decades.
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Objectives: To evaluate the compliance with adjuvant chemotherapy 
for completely resected non-small cell lung cancer (NSCLC).
Methods: Between January 2004 and May 2006, the patients with 
ECOG status 0 or 1 who underwent complete resection for NSCLC 
were referred to the oncologists for the adjuvant chemotherapy. Plati-
num-based adjuvant chemotherapy was performed with 3 or 4 cycles 
according to the protocol or the preference by oncologists. 
Results: Two hundred and thirty-two patients were enrolled in the pro-
spective data collection. Median age was 60.9 years and 76.7 % were 
male. Stage IB, II and III were 34.9%, 28.8% and 36.2%, respectively. 
Eleven patients (4.7%) completed one cycle, 8 (3.4%) completed two, 6 
(2.6%) completed three and 142 patients (61.2%) completed all planned 
cycles. Sixty ﬁve patients (28%) received no therapy. The causes of 
start failure for adjuvant chemotherapy consisted of decreased postop-
erative performance status (n=39), refusal such as ﬁnancial problems 
(n=13) and distant metastasis at initial follow up (n=2). The causes 
of cessation during adjuvant chemotherapy were composed of severe 
adverse effects (n=15), aggravation of disease with newly developed 
metastasis (n=4) and others (n=6). The mortality related to the adjuvant 
chemotherapy was 0.86%(n=2) due to pneumonia and sepsis.
Univariate analysis showed that age, postoperative complications and 
the in-hospital duration were the signiﬁcant factors for the completion 
of adjuvant chemotherapy. Preoperative pulmonary function, smoking 
history, surgical extent (lobectomy versus pneumonectomy) and video-
assisted thoracoscopic surgery were not signiﬁcant. Multivariate analy-
sis demonstrated statistically signiﬁcant differences in compliance with 
only age. Increasing age was associated with decreased compliance. 
Mean age was 59 years old in patients with completion of adjuvant 
chemotherapy compared with 64 years old in those who did not achieve 
the satisfactory chemotherapy. 
Conclusion: Adjuvant chemotherapy for completely resected non-
small cell lung cancer is performed with satisfactory compliance 
about 60%. Age plays an important role in the compliance of adjuvant 
chemotherapy. Elderly subsets will be examined to help determine the 
effect of age on compliance and outcome.
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